For laboratory research use only — not for human or veterinary use. Not evaluated by the U.S. FDA.
Growth Factor Analog Peptide
IGF-1 LR3
An 83-amino-acid IGF-1 analog engineered for reduced binding-protein affinity and prolonged activity, studied for anabolic and growth-related signaling.
Quantity
$64.99
Bundle & save
Delivery
Order by 3:00 PM ET for same-day dispatch
Cutoff 3:00 PM ET · same-day dispatch
Estimated arrival in 2–3 business days
Overnight shipping available
Free shipment protection included
IGF-1 LR3
1 × 1mg · $64.99
99% purity, QC passed
HPLC + mass-spec verified
Shipment protection
Free on every order
Free shipping over $150
Same-day dispatch before 3PM ET
Certificate of Analysis
Third-party tested · Independent analytical lab
1mg
98.02%latest
| Tested | Measured | Purity |
|---|---|---|
| Apr 2026 | 1.20mg | 98.02% |
| Jan 2026 | 1.12mg | 98.59% |
| Nov 2025 | 1.16mg | 97.62% |
| Oct 2025 | 1.15mg | 99.65% |
Frequently researched together
Commonly studied alongside IGF-1 LR3.
Compound information
Technical specifications
Molecular profile
| Type | Synthetic IGF-1 analog |
| CAS number | 143045-27-6 |
| Molecular weight | 9,117.60 g/mol |
| Amino acids | 83 |
| Sequence | MFPAMPLSSL FVNGPRTLCG... |
| Formula | C400H625N111O115S9 |
Storage & stability
- ❄️
Lyophilized (powder)
-20°C · stable 2+ years
- ❄️
Reconstituted
2–8°C · use within 30 days
Sources & references
Peer-reviewed literature, for research context
- Biochemical Journal
Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats
1992·DOI: 10.1042/bj2820091·PMID: 1371669Tomas FM, Knowles SE, Owens PC et al.
View source - Journal of Endocrinology
Superior potency of infused IGF-I analogues which bind poorly to IGF-binding proteins is maintained when administered by injection
1996·DOI: 10.1677/joe.0.1500077·PMID: 8708565Tomas FM, Lemmey AB, Read LC, Ballard FJ
View source - Journal of Endocrinology
IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms
2002·DOI: 10.1677/joe.0.1750019·PMID: 12379487Mohan S, Baylink DJ
View source - American Journal of Pathology
IGF-1 has plaque-stabilizing effects in atherosclerosis by altering vascular smooth muscle cell phenotype
2011·DOI: 10.1016/j.ajpath.2010.10.007·PMID: 21281823von der Thüsen JH, Borensztajn KS, Moimas S et al.
View source - Journal of Endocrinology
Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig
1995·DOI: 10.1677/joe.0.1460247·PMID: 7561636Conlon MA, Tomas FM, Owens PC et al.
View source
Important research notice
Not for human consumption. This product is sold exclusively for laboratory and in vitro research. It is not intended to diagnose, treat, cure, or prevent any disease.
Any research findings referenced on this page are drawn from published, peer-reviewed literature and are provided for educational context only. They are not product claims and should not be read as medical advice.
By purchasing, you confirm you are a qualified researcher and will handle this material in accordance with all applicable laws and institutional guidelines.